KEGG   DRUG: Teplizumab
Entry
D09013                      Drug                                   
Name
Teplizumab (USAN/INN);
Teplizumab-mzwv;
Tzield (TN)
Product
TZIELD (Provention Bio)
Formula
C6462H9938N1738O2022S46
Exact mass
145709.5404
Mol weight
145799.4725
Sequence
(Heavy chain)
QVQLVQSGGG VVQPGRSLRL SCKASGYTFT RYTMHWVRQA PGKGLEWIGY INPSRGYTNY
NQKVKDRFTI SRDNSKNTAF LQMDSLRPED TGVYFCARYY DDHYCLDYWG QGTPVTVSSA
STKGPSVFPL APSSKSTSGG TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG
LYSLSSVVTV PSSSLGTQTY ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPEAAGGP
SVFLFPPKPK DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV YTLPPSRDEL
TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS KLTVDKSRWQ
QGNVFSCSVM HEALHNHYTQ KSLSLSPGK
(Light chain)
DIQMTQSPSS LSASVGDRVT ITCSASSSVS YMNWYQQTPG KAPKRWIYDT SKLASGVPSR
FSGSGSGTDY TFTISSLQPE DIATYYCQQW SSNPFTFGQG TKLQITRTVA APSVFIFPPS
DEQLKSGTAS VVCLLNNFYP REAKVQWKVD NALQSGNSQE SVTEQDSKDS TYSLSSTLTL
SKADYEKHKV YACEVTHQGL SSPVTKSFNR GEC
(Disulfide bridge: H22-H96, H146-H202, H263-H323, H369-H427, H228-H'228, H222-L213, L23-L87, L133-L193)
  Type
Peptide
Remark
ATC code: A10XX01
Product: D09013<US>
Efficacy
Antidiabetic, Anti-CD3 antibody
  Disease
Type 1 diabetes [DS:H00408]
  Type
Monoclonal antibody
Target
CD3 [HSA:915 916 917] [KO:K06450 K06451 K06452]
  Pathway
hsa04658  Th1 and Th2 cell differentiation
hsa04659  Th17 cell differentiation
hsa04660  T cell receptor signaling pathway
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 A ALIMENTARY TRACT AND METABOLISM
  A10 DRUGS USED IN DIABETES
   A10X OTHER DRUGS USED IN DIABETES
    A10XX Other drugs used in diabetes
     A10XX01 Teplizumab
      D09013  Teplizumab (USAN/INN) <US>
USP drug classification [BR:br08302]
 Blood Glucose Regulators
  Antidiabetic Agents
   Glucose Control Agents, Other
    Teplizumab
     D09013  Teplizumab (USAN/INN)
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   CD molecules
    CD3
     D09013  Teplizumab (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D09013
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D09013
Other DBs
CAS: 876387-05-2
PubChem: 96025696
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system